

COMMUNICATION ON TOTAL AMOUNT OF VOTING RIGHTS PURSUANT TO ARTICLE 85-BIS, PARAGRAPH 4-BIS, OF CONSOB REGULATION NO. 11971/1999

Saluggia, December 5th, 2025 – Diasorin S.p.A. (“Diasorin” or the “Company”) hereby announces that some shareholders, holding equity interests lower than 3% of the overall voting rights – waived to the accrued increased voting rights, for overall no. 119,105 ordinary shares of the Company.

In accordance with Article 85-*bis* paragraph 4-*bis*, of Consob Regulation no. 11971/1999, the total amount of the voting rights is presented below, together with the number of shares making up the share capital:

	Status after assignment of increased voting rights			Status before assignment of increased voting rights		
	Number of shares making up share capital	No. of voting rights	Euro	Number of shares making up share capital	No. of voting rights	Euro
Total amount, of which:	55,948,257	88,041,075	55,948,257	55,948,257	88,160,180	55,948,257
Ordinary shares without increased voting rights ISIN IT0003492391 (regular dividend) Current coupon: no. 21	23,855,439	23,855,439	-	23,736,334	23,736,334	-
Ordinary shares with increased voting rights ISIN IT0005188385 (regular dividend) Current coupon: no. 21	32,092,818	64,185,636		32,211,923	64,423,846	

The Special List, updated in accordance with Article 9-*quater* of the Company By-Laws, is available on the Company website <https://int.diasorin.com/>, in the Section “Company/Governance/Ownership Structure/Loyalty shares”.

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 30 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at www.diasorin.com

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

INVESTOR RELATIONS

Riccardo Fava

Corporate VP Communication, ESG & Investor Relations
riccardo.fava@diasorin.it

Eugenia Ragazzo

Corporate Investor Relations & ESG Analyst
eugenia.ragazzo@diasorin.it